Japanese
English
- 有料閲覧
- Abstract 文献概要
- 1ページ目 Look Inside
- 参考文献 Reference
要約 目的:網膜静脈分枝閉塞症に対するベバシズマブ硝子体内注射の効果の報告。対象と方法:黄斑浮腫を伴う網膜静脈分枝閉塞症34例34眼を対象とした。男性10例,女性24例で,平均年齢は70歳である。ベバシズマブは1.25mgを硝子体内に注射した。6か月以上の経過を追跡し,logMAR 0.3以上の変化を改善または悪化とした。結果:視力は20眼(59%)で改善し,中心窩厚は532±216μmから315±144μmに有意に変化した(p<0.01)。27眼(79%)で黄斑浮腫が再発した。ベバシズマブの追加治療を19眼(56%)に行い,黄斑部の光凝固を14眼(41%)に行った。結論:網膜静脈分枝閉塞症に続発した黄斑浮腫に,ベバシズマブ硝子体内注射は短期的には有効である。
Abstract. Purpose:To report the outcome of intravitreal injection of bevacizumab for branch retinal vein occlusion(BRVO). Cases and Method:This study was made on 34 eyes of 34 patients with BRVO. The series comprised 10 males and 24 females. The age averaged 70 years. Each eye received intravitreal injection of 1.25 mg bevacizumab. Cases were followed up for 6 months or longer. Change in logMAR visual acuity by 0.3 or more was judged as improvement or deterioration. Results:Visual acuity improved in 20 eyes(59%). Foveal thickness averaged 532±216μm before and 315±144μm after treatment. The difference was significant(p<0.01). Macular edema recurred in 27 eyes(79%). Treatment with bevacizumab was repeated in 19 eyes(56%). Macular photocoagulation was performed in 14 eyes(41%). Conclusion:Intravitreal injection of bevacizumab is effective for BRVO on a short-term basis.
Copyright © 2009, Igaku-Shoin Ltd. All rights reserved.